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Monocytes in patients with systemic lupus erythematosus (SLE) are hyperstimulatory for T lymphocytes.
We previously found that the normal program for expression of a negative costimulatory molecule
programmed death ligand-1 (PD-L1) is defective in SLE patients with active disease. Here, we investigated
the mechanism forPD-L1dysregulation on lupusmonocytes.Wefound that PD-L1expressiononcultured
SLE monocytes correlated with TNF-a expression. Exogenous TNF-a restored PD-L1 expression on lupus
monocytes.Conversely,TGF-binverselycorrelatedwithPD-L1inSLEandsuppressedexpressionofPD-L1
on healthy monocytes. Therefore, PD-L1 expression in monocytes is regulated by opposing actions of
TNF-a and TGF-b. As PD-L1 functions to fine tune lymphocyte activation, dysregulation of cytokines
resulting in reduced expression could lead to loss of peripheral T cell tolerance.
M
onocytes and dendritic cells from SLE patients display aberrant phenotypes, namely abnormal cytokine
production,defectivephagocytosisofapoptoticcells,andhyperstimulatoryactivityforallogeneicCD4
1
T cells
1–3. The mechanism which leads to dysregulated lymphocyte activation in SLE has not been
elucidated, but most likely depends on differential levels of positive and negative costimulatory molecules
expressed on antigen presenting cells (APCs)
4,5. PD-L1 (B7-H1 or CD274) functions as a critical regulatory
protein to maintain T cell self-tolerance
6, and could play a major role in determining monocyte activity in SLE.
PD-L1, expressed on hematopoietic and parenchymal cells, binds to programmed death-1 (PD-1) to inhibit T
cell receptor-mediated proliferation and induce T cell anergy
6. Engagement of the PD-1 pathway is essential in
suppressing autoimmunity, as originally demonstrated in mice lacking PD-1 expression that developed a disease
similar to SLE
7. Blockade of PD-1 has been shown to affect disease activity in a lupus mouse model
8,9. PD-L1
deficiency does not by itself lead to SLE, but exacerbates systemic autoimmunity in lupus-prone mice
6,10. The
mechanistic link between PD-1 or PD-L1 expression and the pathogenesis of human SLE is not well understood.
Polymorphisms in the PD-1 gene are associated with SLE susceptibility in some populations of adults and
children
11–15. However, PD-L1 gene polymorphisms were not associated with SLE
16,17.
PD-L1expressionisloworabsentonmonocytesexvivo
18,19.WhenPBMCareculturedovernightintheabsence
ofstimulation,PD-L1expressionisup-regulatedonhealthymonocytesandmyeloidDCs.Incontrast,wefounda
diminutiveinductionofPD-L1onAPCsfrompatientswithactiveSLE.Cellsfrompatientsinremission regained
PD-L1expression,suggestingareversiblemechanismforregulationofPD-L1
19.Theexperimentalculturesystem
encompasses two abnormal processes that occur in SLE: the APC response to apoptotic cells and lymphocyte
response to autologous antigens. The failure of APCs to up-regulate PD-L1 may occur in vivo and contribute to
the breakdown of self-tolerance in SLE patients.
Cytokines abnormally expressed in SLE have been implicated in the regulation of PD-L1
18,20–26. Specifically,
TNF-a has been associated with increased PD-L1 expression on synovial and peripheral macrophages derived
from patients with rheumatoid arthritis
24, whereas TGF-b inhibits PD-L1 expression on renal tubular cells
21.
Therefore,thereducedexpressionofPD-L1onlupusmonocytesmaybetheresultofalteredcytokineproduction
ex vivo.
In this report we investigated the role of cytokines in regulating expression of PD-L1 in SLE. During active
disease, the overexpression of TGF-b correlated with decreased levels of PD-L1 surface protein on lupus mono-
cytes. Deficient PD-L1 expression could be restored in vitro by TNF-a, a factor required to induce PD-L1
expressiononhealthymonocytes.PD-L1wasnotinducedonisolatedSLEmonocytesormyeloidDCs,indicating
that PD-L1 expression was not inhibited by SLE lymphocytes. TNF-a induced expression of PD-L1 mRNA in
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healthy control cells, suggesting opposing transcriptional regulation
by these two cytokines. These findings demonstrate that abnormal
cytokine production may lead to poor PD-L1 expression on mono-
cytes, contributing to the hyperstimulatory phenotype found in SLE.
Results
Aberrant expression of TNF-a and TGF-b correlates with PD-L1
levels on SLE monocytes. To investigate the mechanism for dys-
regulation of PD-L1 expression in SLE, PBMC from patients and
healthy controls were cultured for 24 hours without stimulation.
PD-L1 surface protein on monocytes was assayed by flow cyto-
metry (Supplemental Figure 1). We observed no PD-L1 expression
at the initiation of culture on either monocytes or myeloid DC from
SLEpatientsorcontrols.PD-L1proteinwasfirstdetectedby8 hours,
increased at 24 hours, and remained high until day five (Sup-
plemental Figure 2). Deficient PD-L1 expression on cultured SLE
monocytes during active disease was not related to specific me-
dications, and is unlikely to be a gene defect, as most patients were
able to restore PD-L1 protein during remission
19. Hence we
postulated that dysregulated cytokine production in SLE may lead
to decreased expression of PD-L1 on SLE APCs. Supernatants from
control and SLE PBMC cultures were assayed for expression of
cytokines known to associate with the severity of SLE, including
IFN-c, IFN-a, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-a, and TGF-b.
The most significant differences between SLE patients and healthy
controls were found in the expression of TNF-a and TGF-b.
Interestingly, TNF-a, reported to be increased in SLE patient
serum
25, was expressed at 2.7-fold higher levels by PBMC from
healthy controls compared to SLE patients in our experiments
(mean, 129.4 pg ml
21 vs. 44.2 pg ml
21,F i g u r e1 A ) .T h o u g h
production of TNF-a was restored in some SLE patients during
remission, the mean was still significantly reduced compared to
controls (81.7 pg ml
21). In contrast, TGF-b was induced to higher
levels in both active SLE(2393 pg ml
21) and remission (3914 pg ml
21)
compared to controls (1684 pg ml
21, Figure 1B). Among other
cytokines tested, IFN-c, IL-4, IL-10, IFN-a and IL-2 were
undetectable in supernatants from most subjects, an expected result
considering that T lymphocytes were unstimulated. Moreover,
expression of neither IL-6 nor IL-8 was significantly different in
controls compared to SLE patients (data not shown).
We then tested for correlations between TNF-a,T G F - b and PD-L1
expression. The expression of PD-L1 significantly correlated with
TNF-a during disease remission (Figure 1C), suggesting that express-
ion of TNF-a may be required to restore PD-L1 expression on lupus
monocytes. In contrast, high expression of TGF-b was significantly
correlated with low PD-L1 levels during active disease (Figure 1D). In
PBMC from healthy controls, there was no correlation between
Figure 1 | PD-L1 levels correlated with TNF-a in remission and with TGF-b in patients with active disease. (A) and (B) Levels of TNF-a and TGF-b
detected in supernatants from PBMC cultured overnight without stimulation. Horizontal lines represent mean values. Cytokine levels between healthy
controls and SLE patient groups were compared using the Wilcoxon-Mann-Whitney test. Significance was assigned where p,0.05; N.S., not significant.
(C) PD-L1 protein levels on monocytes in the same culture was assayed by flow cytometry; TNF-a positively correlated with PD-L1 expression on
monocytesinSLEpatientsinremission(dashedline).(D)TGF-bnegativelycorrelatedwithPD-L1proteininSLEpatientswithactivedisease(solidline).
Correlations were analyzed by the Spearman’s rank correlation test.
www.nature.com/scientificreports
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expressed PD-L1. Thus, correlation analyses suggested that TGF-b
suppresses PD-L1 expression during active SLE, while TNF-a induces
PD-L1 expression during remission and in healthy controls.
PD-L1 surface protein is induced by TNF-a and down-regulated
by TGF-b. We have previously shown that cells from patients in
remission restored PD-L1 expression, suggesting a reversible me-
chanism for regulation of PD-L1 during the disease course of
SLE
19. Therefore, we tested the hypothesis that expression of PD-
L1 on SLE cells can be restored by TNF-a. To determine whether
TNF-a is normally required for induction of PD-L1, we examined
the change of PD-L1 expression on healthy cells treated with a TNF-
a neutralizing antibody. Blocking TNF-a resulted in significantly
decreased expression of PD-L1 surface protein on monocytes from
healthy controls (Figure 2A). Likewise, treatment with TGF-b
significantly suppressed PD-L1 surface protein on healthy mono-
cytes. Addition of neither recombinant TNF-a nor TGF-b block-
ing antibody affected PD-L1 expression on healthy cells.
We found that TNF-a significantly induced PD-L1 protein ex-
pression on SLE remission monocytes (Figure 2B). However, induc-
tion of PD-L1 by TNF-a was not significant in patients with active
disease. Of note, TNF-a treatment resulted in little induction of PD-
L1 on myeloid DCs (data not shown), indicating that expression of
PD-L1 is differentially regulated on monocytes and myeloid DCs.
Blocking TGF-b with a mAb was not sufficient to restore PD-L1 on
SLEmonocytes(Figure2B).ThedatasuggeststhatrestorationofPD-
L1 expression on SLE monocytes may require TNF-a and other
positive regulatory factors in addition to blocking inhibitory TGF-
b. TNF-a is normally required for PD-L1 induction, whereas TGF-b
may oppose the induction in active SLE. As SLE monocytes express
low levels of PD-L1, inhibition of TNF-a by mAb or addition of
recombinant TGF-b was not able to reduce the protein expression
further (Figure 2B).
PD-L1 expression is induced by monocyte-derived factors.
Cytokines that dysregulate expression of PD-L1 can be derived
from either aberrant SLE myeloid or lymphoid cells
2,27. To identify
other cell populations affecting PD-L1 expression on monocytes, we
compared the expression of PD-L1 on isolated CD14
1cells cultured
alonewiththatonmonocytesintotalPBMCcultures.Noexpression
ofPD-L1wasdetectedonisolatedmonocytespriortocultureattime
0 (Supplemental Figure 2). PD-L1 was induced on isolated healthy
CD14
1 monocytes cultured overnight without stimulation, indi-
cating that monocyte-intrinsic factors are sufficient for induction
of surface PD-L1 (Figure 3A and B). However, the depletion of
CD14
2 cells decreased expression of PD-L1 on myeloid DCs and
monocytes from healthy donors that had higher PD-L1 expression
(Figure 3B), suggesting that induction of PD-L1 could be enhanced
by lymphocytes. Both regulatory T cells and NKT cells have been
previously reported to induce PD-L1 expression, and may play roles
in defective PD-L1 induction in SLE
28,29. There was no change in
the level of PD-L1 expression on either isolated SLE monocytes or
myeloid DCs as compared to total PBMCs (Figure 3C and D),
demonstrating that PD-L1 expression is not suppressed by SLE
lymphocytes. Rather, SLE APCs lack intrinsic factors required for
PD-L1 induction.
We next tested the direct effect of cytokines on isolated CD14
1
monocytesandmyeloidDCs.Theinduction ofPD-L1expressionon
monocytes after treatment of total PBMCs with TNF-a that we
showed in Figure 2 was similarly demonstrated in isolated SLE
monocytes, where expression of PD-L1 was significantly induced
in four out of five patients (Figure 3E). Blocking TGF-b did not
changed expression of PD-L1 protein on isolated SLE monocytes
(Figure 3F), whereas blocking TNF-a significantly decreased PD-
L1 expression on isolated healthy monocytes (Figure 3G).
Moreover, TGF-b treatment of isolated monocytes resulted in sig-
nificant repression of PD-L1 in healthy donors (Figure 3H). These
findings support the hypothesis that intrinsic defects in SLE mono-
cyte cytokine expression result in poor PD-L1 induction.
Expression of PD-L1 correlated with TNF-a in monocyte culture
supernatants. In order to determine whether or not PD-L1 is
induced by monocyte-intrinsic factors, we assayed levels of TNF-a
and TGF-b in purified monocyte culture supernatants. Increased
TNF-a was detected in supernatants from healthy monocytes
(mean, 157 pg/ml) compared to those from patients with active
disease (Figure 4A, p 5 0.027). TNF-a expression was higher in
SLE remission (109 pg/ml) compared to active disease (37 pg/ml),
but the difference was not statistically significant (p 5 0.067).
Expression of PD-L1 on isolated monocytes from remission pa-
tients also significantly correlated with TNF-a (Figure 4B). These
Figure 2 | PD-L1 surface protein on SLE APCs is differentially regulated by TNF-a and TGF-b. (A) Control PBMC were treated for 24 hours.
ExpressionofPD-L1onCD14
highCD11c
1monocyteswasassayedbyflowcytometry,andisexpressedasfoldinductionoveruntreatedcells.(B)Induction
ofPD-L1onmonocytes inSLEPBMCtreatedfor24 hours orculturedinmediaalone.InductionofPD-L1proteinbycytokinetreatmentswastestedfor
significance by the Wilcoxon signed-rank test. Results were derived from multiple independent experiments.
www.nature.com/scientificreports
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induce PD-L1. Conversely, substantial expression of TGF-b was
detected in monocyte supernatants (Figure 4C). Isolated mono-
cytes from SLE patients produce higher level of TGF-b compared
to healthy controls (active disease 5 3527 pg/ml; remission 5
2189 pg/ml; healthy controls 5 1446 pg/ml), but the difference was
insignificant. No correlation was found between PD-L1 protein level
andTGF-b(Figure 4D).Thesedata suggestthatcelltypesother than
monocytes can also produce TGF-b to counter-regulate level of PD-
L1 on monocytes.
Opposing effects of TNF-a and TGF-b on PD-L1 mRNA
expression. PD-L1 expression has been reported to be regulated at
both transcriptional and translational levels in different model
systems
30–32. PD-L1 mRNA expression was assayed in cultured
PBMC from SLE patients and healthy donors. We found that PD-
L1mRNAwasexpressed incellsfromallcontrolsubjects(median6
S.E.M.50.2260.16,Figure5A),andwasonaverageten-foldhigher
thaninSLEpatients(0.01860.09foractivedisease,0.02460.08for
remission), although the differences were not significant. Parallel
flow cytometry assays demonstrated that some patients with active
disease and high PD-L1 mRNA expression had little to no PD-L1
protein on the surface of monocytes, myeloid DCs, or lymphocytes.
Moreover, there was no correlation between PD-L1 mRNA and pro-
tein expression in any subject group (data not shown), indicating that
restoration of PD-L1 surface protein was not entirely dependent upon
mRNA expression, but may require additional translational signals, as
demonstrated in other biological models
30,31.
The signaling pathways mediated by TNF-a and TGF-b are well
documented
33,34. However, it is unclear how these distinct pathways
converge to counter-regulate PD-L1 expression. We next demon-
strated that PD-L1 mRNA is differentially regulated by TGF-b and
TNF-a. PD-L1 mRNA was significantly induced in SLE cells treated
with TNF-a (Figure 5B), whereas blocking TNF-a prevented induc-
tion of PD-L1 mRNA in three of six healthy donors (Figure 5C).
Similarly, TGF-b significantly inhibited expression of PD-L1 mRNA
in control PBMC (Figure 5D). Overall, these data support a model
in which PD-L1 gene expression is tightly regulated by the action
of two opposing cytokines, TNF-a and TGF-b.
Discussion
Although functional defects in monocytes and DCs are well known
in SLE, the underlying molecular mechanisms are not fully under-
stood. The present study addresses the mechanism for regulating
Figure 3 | ExpressionofPD-L1onisolatedCD14
1cellsisnotentirelydependentonlymphocytes. (A)and(C)Representativehistogramsdemonstrate
PD-L1 induction on total PBMC or isolated CD14
1 cells from a control subject and an active SLE patient. Protein expression was assayed by flow
cytometry after culturing cells for 24 hours without stimulation. (B) and (D) PD-L1 expression on monocytes gated from total PBMC compared to
isolated monocytes and myeloid DCs in eight healthy controls and eight SLE patients. (E) and (F) Fold induction of PD-L1 MFI on isolated CD14
1 SLE
monocytes treated withTNF-a or withanti-TGF-bmAb. (G)and(H) Foldinduction ofPD-L1 MFI onisolated CD14
1monocytes from healthy donors
treatedwithanti-TNF-amAborwithrecombinantTGF-b.InductionwasquantifiedbydividingtheMFIofcytokine-treatedsamplesbythatofuntreated
cells, and tested for significance by the Wilcoxon signed-rank test.
www.nature.com/scientificreports
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versus anti-inflammatory activity of APCs. PD-L1 expression is
regulated by a balance of cytokines with known importance in
SLE
21,35. In other inflammatory diseases including rheumatoid arth-
ritis, infection, and malignancies, PD-L1 expression has been
reported to be up-regulated by inflammatory cytokines
36,37. In con-
trast, we previously demonstrated deficient PD-L1 surface express-
ion on monocytes and myeloid DCs with active SLE
19. We have
shown here that the defect on SLE monocytes can be attributed
partially to overexpression of TGF-b, which inhibits PD-L1 express-
ion,andpartlytodecreasedproductionofTNF-arequiredforinduc-
tion of PD-L1 mRNA and surface protein expression.
In the current study, some patients with active SLE produced less
TNF-a, a trait reported to correlate with SLE-associated HLA-DR
alleles
38–40. Whether children with SLE expressing less TNF-a in
correlation with decreased PD-L1 expression on monocytes carry
the polymorphisms leading to low TNF-a expression is not known.
Expression of PD-L1 may also be influenced by the availability of
receptorsandinduciblesignalingmoleculesandtranscriptionfactors
in the TNF receptor signaling pathway. TNF receptor expression is
reportedly normal in SLE, though decreased expression of TNF-a
signaling proteins in SLE patients has been reported
41,42, and could
accountforthedecreasedPD-L1inductionobservedinunresponsive
SLE monocytes from some patients, although most patient mono-
cytes respond well to TNF-a. Anti-TNF-a therapy is effective in
treatingrheumatoid arthritis, auto-inflammatory diseases, and some
SLE patients. However, TNF-a blockers have been shown to trigger
lupus in some patients, and induce lupus-related autoantibody pro-
duction. The onset of autoimmunity triggered by TNF-a blockers
may be in part through activation of plasmacytoid dendritic cells,
which lead to enhanced production of IFN-a
43. Our data suggests
thatlackofnormalTNF-ainductionofPD-L1expression couldalso
contribute to disease. These studies underline the complex role of
TNF-a in autoimmunity, with different effects at distinct cellular
targets.
The role of TGF-b in the pathogenesis of SLE remains unclear.
Previous studies have shown decreased TGF-b production by SLE
lymphocytes
44, in contrast to our increase in TGF-b production by
SLEPBMCwithconcurrentsuppressionofPD-L1.However,TGF-b
therapies in lupus-prone mice have yielded mixed results
45, perhaps
because TGF-b contributes to the development of both proinflam-
matory Th17 cells and regulatory T cells (Treg)
46. TGF-b is essential
for differentiation of murine Treg, but its role in human Treg is less
well defined. PD-L1 has been shown to induce Treg in mice and
humans
28,47, suggesting defective induction of PD-L1 may lead to
reduced number of functional Treg observed in SLE patients
48.
Figure 4 | MonocytesproduceTNF-atoinduceexpressionofPD-L1. (A)TNF-awasassayedinsupernatantsfromisolatedCD14
1monocytescultured
overnight without stimulation. Horizontal lines represent mean values. (B) PD-L1 protein levels on monocytes in the same culture was assayed by flow
cytometry; TNF-a positively correlated with PD-L1 expression on monocytes in SLE patients in remission. (C) TGF-b protein levels in monocyte
supernatants. (D) Correlation betweenTGF-bandPD-L1 protein levelson monocytes. Cytokine levelsbetweenhealthy controls and SLEpatient groups
were compared using the Wilcoxon-Mann-Whitney test. Correlations were determined by the Spearman’s rank correlation test.
www.nature.com/scientificreports
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in SLE
49, though whether or not this leads to increased surface pro-
tein expression and higher sensitivity to TGF-b signaling is not
known.
TGF-binhibitionofPD-L1expressiononmonocytesisconsistent
with a previous finding that TGF-b suppresses PD-L1 expression on
murinerenalproximaltubularepithelialcells,allowingtheactivation
of CD8
1 cytotoxic T cells
21. Our data suggest that overexpression of
TGF-b during active SLE can suppress PD-L1 by inhibiting protein
and mRNA expression. It has been shown that TGF-b can inhibit
production of TNF-a in mouse macrophages
50, but further work is
required to determine whether TGF-b suppresses PD-L1 expression
directly, or through inhibition of TNF-a. TGF-b and TNF-a could
directly counter-regulate gene expression, as occurs in mucosal epi-
thelial cells, where TGF-b inhibits recruitment of the transcription
factor NFkB to the IL-6 promoter
51.
Our results differed from previous findings, which have shown
increased levels of TNF-a and diminished expression of TGF-b in
SLE patients
53. In our experimental system, levels of cytokines were
measured in culture supernatants of unstimulated cells, whereas
othersreportedcytokinelevelsinserumorusingareporterassay
44,52.
AnothergroupmeasuredexpressionofTNF-aandTGF-binculture
supernatants stimulated by adding apoptotic cells
53. Our model sys-
tem may measure in part response to apoptotic cells; more apoptotic
cells were found in SLE PBMC cultures compared to healthy cells.
However,thenumberofapoptoticcellsdidnotcorrelatewithPD-L1
expression, and preliminary experiments showed no effect of addi-
tional apoptotic cells on PD-L1 expression on healthy monocytes.
Thus, SLE monocytes may be resistant to apoptotic cell signals.
Subject selection could also influence reported cytokine profiles,
thoughneitheragenorimmunosuppressive medicationsignificantly
affected cytokine or PD-L1 expression in pediatric SLE patients in
our cohort
19.
WhilecontrolmonocytesexpressedPD-L1intheabsenceofother
celltypes,ourresultsdidnotruleoutthepossibilitythatlymphocytes
normally contribute to expression of PD-L1 on APCs. We noted
decreased PD-L1 expression on cultured isolated myeloid DCs and
monocytes in some control subjects and patients. Interestingly, we
found that PD-L1 expression on SLE monocytes and myeloid DCs
could be partially restored by co-culturing with allogenic CD4
1 T
cells from healthy donors (preliminary data). SLE T cells present
multiple signaling aberrations
27, and are reduced in number of func-
tional Treg
48, which could be required for induction of PD-L1 on
APCs
28. It remains to be determined whether correcting SLE T cell
defects can alter expression of PD-L1 on APCs.
Although most SLE patients with active disease expressed PD-L1
mRNA, surface protein expression was generally low or undetect-
able. The lack of correlation between mRNA and protein suggests
Figure 5 | PD-L1mRNAisinducedbyTNF-aandsuppressedbyTGF-b. TotalPBMCwereculturedfor24 hours.PD-L1mRNAexpressionwasassayed
by RT-qPCR for each subject in triplicate. (A) Relative PD-L1 mRNA expression in controls and lupus patients was represented by the scatter plot.
Horizontallinesrepresentmedians.BaselinemRNAexpressionwassetat5310
23.ExpressionofPD-L1mRNAincontrolsubjectsandSLEpatientswere
compared using the Wilcoxon-Mann-Whitney test. P.0.05 between all groups. (B) PD-L1 mRNA in SLE PBMC treated with recombinant TNF-a. (C)
and (D) PD-L1 mRNA levels in healthy donor PBMC treated with anti-TNF-a or TGF-b. Induction of PD-L1 mRNA by cytokines was tested for
significance by the Wilcoxon signed-rank test.
www.nature.com/scientificreports
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tiveinductionofPD-L1proteinonAPCs.WehypothesizedthatPD-
L1 could be cleaved from the cell surface. However, soluble PD-L1
was undetectable in culture supernatants and in SLE plasma when
assayed with a sensitivity of 60 pg/ml. Post-transcriptional and
translational regulation of PD-L1 has been shown in different bio-
logical models. In human trophoblast cells, epidermal growth factor
increasesrecruitmentofPD-L1transcriptstoactiveribosomes
31,and
IFN-c induces PD-L1 protein expression by inhibiting miRNA in
cholangiocytes
30. We are currently investigating whether additional
translational regulatory mechanisms are involved in determining
expression of PD-L1 surface protein on APCs.
We cannot rule out a role for additional cytokines in PD-L1 regu-
lation in SLE. Type I and II IFNs are critical mediators of SLE
1, and
known inducers of PD-L1 expression
20,22. However, neither IFN-c
nor IFN-a were detected in unstimulated PBMC cultures in our
experiments or by others
54, and thus are unlikely to be involved in
the regulation of PD-L1 in our model system. IL-10 signaling
through STAT3 has been shown to up-regulate PD-L1 protein in
dendritic cells
55,56, but in our experiments IL-10 was only detected
at minimal levels in some unstimulated PBMC cultures (data not
shown). IL-6 also signals through STAT3 to induce PD-L1 express-
ion
56. While IL-6 was detected in SLE culture supernatants (data not
shown), the direct role of IL-6 in the regulation of PD-L1 in SLE has
yet to be explored. Deficient PD-L1 expression on SLE APCs may
result from the cytokine environment in vivo. Therefore, we assayed
levels of 16 plasma cytokines in 66 SLE patients in remission, 48
patients with active disease, and 65 healthy donors. We found no
correlation between plasma cytokine levels and PD-L1 expression.
These data do not exclude the possibility that cytokines may have an
effect on phenotypes of APCs in lymphoid tissues, which are inac-
cessible for human studies.
In the current study, we identified TNF-a and TGF-b as counter-
regulators of PD-L1 expression. Monocytes are programmed to
respond in autologous culture to generate intrinsic factors required
tostimulate expressionofPD-L1,andthereducedexpressionofPD-
L1onSLEmonocyteswasnotdependentonothercelltypes.Thelack
of proper induction of PD-L1 may contribute to the hyperstimula-
tory phenotype of SLE APCs, resulting in reduced peripheral T cell
tolerance. Better characterization of mediators regulating PD-L1
may lead to promising new therapeutic targets aimed at restoring
PD-L1 expression in SLE patients.
Methods
Human subjects and blood samples. The research protocol was approved by the
InstitutionalReviewBoardofSeattleChildren’sHospital.PediatricSLEpatientswere
recruited in the Seattle Children’s Hospital Rheumatology Clinic; age-matched
healthy pediatric volunteers were recruited through an ongoing project to study
pediatric autoimmune diseases. Informed assent and consent were obtained. All
lupus patients fulfilled the current American College of Rheumatology (ACR)
classification criteria for SLE diagnosis
57. Subjects were excluded for infections,
malignancy, or other autoimmune diseases that may affect PD-L1 expression.
Peripheral venous blood was collected into Cell Preparation Tubes (CPT, BD
Biosciences, San Jose, CA). PBMC were isolated and frozen in 7% DMSO (Sigma-
Aldrich,St-Louis,MO).SLEscoresweredeterminedbytheSLEdiseaseactivityindex
(SLEDAI)
58.ActivediseasewasdefinedbyaSLEDAI.4toexcludepatientswithonly
laboratory abnormalities.
Cellcultureandflowcytometry.PBMCwerethawed,washedanddilutedto10
6cells
ml
21 in culture medium consisting of RPMI 1640 supplemented with L-glutamine
(CellGro, Manassas, VA), and 10% heat-inactivated human AB serum (Valley
Biomedical, Winchester, VA), 1% penicillin/streptomycin (CellGro) and 0.1% b-
mercaptoethanol. All assays were performed using frozen PBMC samples, as we
previously determined that freezing does not influence PD-L1 expression. Cells were
plated in round-bottom 96-well plates, and cultured for 24 hours without
stimulation. Between 60–85% of total PBMC were recovered after overnight
culturing. PBMC were surface-stained using fluorochrome-conjugated mAb,
including: anti-CD3 (UCHT1), anti-PD-L1 (MIH1) (eBioscience, San Diego, CA),
anti-CD11c (B-ly6), and anti-CD14 (MjP9) (BD Biosciences), with isotype-matched,
fluorochrome-labeled antibodies as controls. All samples were blocked using 0.5%
human AB serum and anti-FcR antibody (Miltenyi, Bergisch GladbachGermany)
prior and during staining. Flow cytometry was performed using an LSR II cytometer
(BD Biosciences), and the data analyzed using FlowJo software (Tree Star, Ashland,
OR). Examination ofsurface markers on normalPBMC determinedthat the PD-L1
1
cells segregated into monocyte (CD14
highCD11c
1) and immature myeloid DC
(CD14
lowCD11c
1) populations (Supplemental Figure 1)
19,59. A similar expression
profileofPD-L1wasobtainedwhencellsweregrownonstandardtissuecultureplates
compared to polystyrene-treated plates. For cytokine experiments, PBMC were
cultured for 24 hours in the culture medium, or with 10 ng ml
-1 of recombinant
cytokines TNF-a (eBioscience) or TGF-b (R&D systems). In some experiments, cells
were treated with 10 mgm l
21 of mAb neutralizing TNF-a or TGF-b (R&D systems).
CD14
1 monocytes and myeloid DCs were sorted by negative selection using the
EasySep human monocyte enrichment kit (StemCell Technologies, Inc., Vancouver,
BC, Canada), with purity .90%. Endotoxin levels in PBMC and isolated monocytes
were determined to be ,1E Um l
21 by Limulus amoebocyte lysate clot assay
(Associates of Cape Cod, East Falmouth, MA). Expression of PD-L1 on monocytes
and myeloid DC was determined by subtracting the background PD-L1 mean
fluorescence intensity (MFI) of the CD3
2CD14
2CD11c
2 subset, which was
consistently negative for PD-L1 expression, similar to the isotype controls.
Cytokine analysis. All cytokine assays were performed on culture supernatants
(24 hours PBMC culture) by the Cytokine Analysis Laboratory at the Fred
HutchinsonCancerResearchCenter.CytokinesweremeasuredbytheLuminexassay
system with a latex bead-based multianalyte system (Luminex, Austin, TX). TGF-b
was assayed by ELISA (R&D Systems).
Real-time reverse transcriptase-qPCR (RT-qPCR). Total RNA was extracted from
PBMC using the RNeasy Plus Micro Kit (Qiagen, Germantown, MD). Real-time RT-
qPCR analysis was performed using a Bio-Rad iCycler, in 25-ml reaction mixtures
withSYBRgreenPCRmastermix(SABiosciences,Frederick,MD).Theprimers used
for amplifying PD-L1 mRNA (Gene Bank accession number: NM_014143) were
sense: 59-GGCATTTGCTGAACGCAT-39; antisense: 59-CAATTAGTGCAGCCA-
GGT-39. For GAPDH, the primers were sense: 59-TGCACCACCAACTGCTTA-39;
antisense: 59-GGATGCAGGGATGATGTTC-39. Standard curves were determined
for each primer set by serial dilution. Expression of each cDNA was calculated from
the cycle threshold (CT). The relative PD-L1 mRNA expression was determined by
normalizingtoGAPDHmRNA,anddividingbythepercentageofmonocytesineach
sample, where PD-L1 is predominantly expressed.
Statistical analyses. STATA statistical software was used to perform all analyses
(Stata Corporation, College Station, TX).
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